Blood pressure – lower targets, greater challenges
Abdullah Shehab,M. Kendall
DOI: https://doi.org/10.1046/j.0269-4727.2003.00519.x
2003-12-01
Journal of Clinical Pharmacy and Therapeutics
Abstract:The world health organization has estimated that high blood pressure causes one in eight deaths world wide making hypertension the third leading killer in the world (1). The seventh joint national committee (JNC-7) report was recently published in the Journal of the American Medical Association (2) and presents new guidelines for the prevention and management of high blood pressure, based on a review of all the latest scientific literature. The guidelines were developed by the National High Blood Pressure Education Program Coordinating Committee, administered by the National Heart, Lung, and Blood Institute. The report addresses areas including blood pressure measurement and classification, patient evaluation and testing, treatment approaches and monitoring, and certain special considerations (2). The new guidelines categorize blood pressure as normal (<120/80 mmHg), prehypertension (120/ 80 to 139/89), stage 1 hypertension (140/90 to 159/ 99), and stage 2 hypertension (‡160/100). The JNC7 report on hypertension takes a stronger view than its predecessors (3), reclassifying ‘high normal’ blood pressure as ‘prehypertension’ and calling for aggressive treatment, first by changing lifestyle and then with drugs. The guidelines also emphasize the importance of a systolic blood pressure of over 140 mmHg as an important cardiovascular risk factor for people over 50 years of age. Cardiovascular disease risk increases as the blood pressure rises above 115/75 mmHg, increasing 2-fold for each 20/10 mmHg increment. Lowering blood pressure from 140/90 towards the new goal level of 120/80 mmHg will decrease heart attacks (20– 25%), heart failure (50%), stroke (35–40%), kidney disease, and will save lives (2). The blood pressures at which most doctors consider treatment may be beneficial are in fact well above the level at which blood pressure starts to cause harm. JNC-7 emphasizes the importance of aging which is the single most important factor associated with the development of hypertension (4). Unless preventive steps are taken, stiffness and other damage to arteries worsen with age and make high blood pressure more and more difficult to treat. The new prehypertension category reflects this risk and will prompt people to take preventive action early. Data from the Framingham Heart Study suggests that individuals who are normotensive at 55 years of age have a 90% lifetime risk for developing hypertension. So the aim should be to slow the adverse effects of aging and delay the onset of hypertension. In practice lifestyle modification is the only way, at present, to counteract the effects of age and to try to prevent the development of hypertension. JNC-7 recommends that Governments and others should modify working conditions to reduce the excessive demands and time pressures on those living in the developed countries of the world. In addition they should also promote exercise, weight reduction, the consumption of less alcohol and the taking of less sodium in the diet. Specifically JNC-7 recommends change to the ‘DASH’ diet – high in fruits and vegetables, potassium, and calcium – (5). Most important smoking cessation should be encouraged and children and young people should be discouraged from starting to smoke. The JNC-7 guidelines include new data on US control, awareness, and treatment rates for high blood pressure. According to a national survey, 70% of Americans are aware of their high blood pressure, 59% are being treated for it, and 34% of those with hypertension have it under control (6). Those percentages represent a slight improvement over rates for 10 years ago, when 68% of Americans were aware of their high blood pressure, 54% were being treated for it, and 27% of those with hypertension had it under control (6). By contrast, Received 9 September 2003, Accepted 19 September 2003 Correspondence: Dr A. M. A. Shehab, Clinical Investigation Unit, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, UK. Tel.: 0121 414 6874; fax: 0121 414 1344; e-mail: ashehab@doctors.org.uk Journal of Clinical Pharmacy and Therapeutics (2003) 28, 441–443